2025
Histopathologic Progression of Autoimmune Atrophic Gastritis: A Retrospective Review of 180 Specimens From 32 Patients.
Wang X, Jiao J, Huh W, Zhang X. Histopathologic Progression of Autoimmune Atrophic Gastritis: A Retrospective Review of 180 Specimens From 32 Patients. Archives Of Pathology & Laboratory Medicine 2025 PMID: 40509896, DOI: 10.5858/arpa.2025-0030-oa.Peer-Reviewed Original ResearchAutoimmune atrophic gastritisFollow-up biopsiesNeuroendocrine tumorsFollow-upEndoscopic excisionEnterochromaffin-like cell hyperplasiaDevelopment of neuroendocrine tumorsLong-term follow-upKi-67 indexMinimal to mild inflammationImmune-mediated inflammationPathological progressionAverage follow-upEndoscopic surveillance intervalRetrospective reviewSurveillance intervalsKi-67Cell hyperplasiaGastric adenocarcinomaNo significant changesHistological featuresAntibody statusAtrophic gastritisClinical dataIntestinal metaplasiaEpidemiology of Neuroendocrine Neoplasms in the US
Dasari A, Wallace K, Halperin D, Maxwell J, Kunz P, Singh S, Chasen B, Yao J. Epidemiology of Neuroendocrine Neoplasms in the US. JAMA Network Open 2025, 8: e2515798. PMID: 40553474, PMCID: PMC12188367, DOI: 10.1001/jamanetworkopen.2025.15798.Peer-Reviewed Original ResearchConceptsDuration prevalenceIncidence rateNational Cancer Institute's SurveillanceNeuroendocrine neoplasmsOverall survivalNeuroendocrine tumorsAge-adjusted incidenceSurvival trends of patientsAnnual age-adjusted incidenceNeuroendocrine neoplasm casesCross-sectional studyHighest incidence ratePrimary siteTrends of patientsInstitute's SurveillanceMain OutcomesPrevalence of neuroendocrine neoplasmsSmall bowelPrimary site of originFactors associated with survivalDiagnosis of early stage diseasePractice patternsPancreatic neuroendocrine tumorsGastrointestinal neuroendocrine tumorsEarly stage diseaseA multi-centre, stratified, open, randomized, comparator-controlled, parallel group phase II trial comparing adjuvant treatment with 177Lu-DOTATATE to standard of care in patients after resection of neuroendocrine liver metastases (NELMAS).
Frilling A, Baum R, Veselkov K, Martinez Del Peral E, Martinez M, Lovelle M, Wu J, Park S, Clift A, Eccles A, Hubber J, Wasan H, Modlin I. A multi-centre, stratified, open, randomized, comparator-controlled, parallel group phase II trial comparing adjuvant treatment with 177Lu-DOTATATE to standard of care in patients after resection of neuroendocrine liver metastases (NELMAS). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps4225.Peer-Reviewed Original ResearchGastro-entero-pancreatic neuroendocrine tumorsNeuroendocrine liver metastasesDisease-free survivalStandard of careGastro-entero-pancreaticResection of LMNeuroendocrine tumorsLu-DOTATATEOverall survivalTumor recurrenceLiver resectionAdjuvant treatmentResection of neuroendocrine liver metastasesEarly detection of recurrent diseaseEfficacy of adjuvant therapyPeptide receptor radionuclide therapyDetection of recurrent diseaseDisease-free survival probabilityAssociated with favorable overall survivalStandard of care armAdjuvant treatment conceptsGa-DOTATATE PET/CTLiver-directed therapiesMacroscopic complete resectionProspective open-labelTumors of the sellar region
Baehring J, Shih H, Chen Z, Santagata S. Tumors of the sellar region. 2025, 245-263. DOI: 10.1093/med/9780198869702.003.0023.Peer-Reviewed Original ResearchSellar regionPrognosis of craniopharyngiomasSpindle cell oncocytomaGranular cell tumorNeuroendocrine tumorsPituitary blastomaClinical presentationCell tumorsPediatric neoplasmsMolecular pathogenesisTumorMolecular featuresAbstract TumorsDiagnosisBlastomaPituicytomaCraniopharyngiomaOncocytomaNeoplasmsPrognosisACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: phase 1b safety/efficacy
Halperin D, Morris M, Ulaner G, Strosberg J, Mehr S, Li D, Soares H, Covington M, Anthony L, Kotiah S, Jacene H, E.T. T, Kunz P, Ferreira D, Li J, Ma K, Rearden J, Moran S, Hope T, Singh S. ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: phase 1b safety/efficacy. Endocrine Abstracts 2025 DOI: 10.1530/endoabs.108.c17.Peer-Reviewed Original ResearchPheochromocytoma and MEN Syndromes
Carr Z, Farela A, Oprea A. Pheochromocytoma and MEN Syndromes. 2025, 333-342. DOI: 10.1093/med/9780190902001.003.0030.Peer-Reviewed Original ResearchMultiple endocrine neoplasiaInadequate surgical resectionManagement of PPGLsRare neuroendocrine tumorsDefinitive surgical managementResection of pheochromocytomaPreoperative medical managementDiligent postoperative careHigh-risk procedurePersistent vasoplegiaResected patientsSurgical resectionNeuroendocrine tumorsPostoperative bleedingRefractory hypertensionVasopressor supportHypertensive crisisPreoperative optimizationEndocrine neoplasiaABSTRACT PheochromocytomaPostoperative periodPerioperative considerationsVentricular dysrhythmiasAnesthesia techniquesPotential complications
2024
Mechanisms of immunotherapy resistance in small cell lung cancer
Nie Y, Schalper K, Chiang A. Mechanisms of immunotherapy resistance in small cell lung cancer. Cancer Drug Resistance 2024, 7: n/a-n/a. PMID: 39802951, PMCID: PMC11724353, DOI: 10.20517/cdr.2024.154.Peer-Reviewed Original ResearchSmall-cell lung cancerImmune checkpoint inhibitorsSociety for Immunotherapy of CancerImmunotherapy resistanceTumor microenvironmentPrimary resistanceAcquired ResistancePrimary resistance to immune checkpoint inhibitorsLung cancerResistance to immune checkpoint inhibitorsMechanisms of immunotherapy resistanceSmall cell lung cancerImmunosuppressive immune cellsImmunotherapy to chemotherapyResistance to immunotherapySociety for ImmunotherapyImmunotherapy of cancerAggressive neuroendocrine tumorCell lung cancerCheckpoint inhibitorsTumor immunogenicityEffective immunotherapyNeuroendocrine tumorsPoor prognosisAntigen presentationConditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
Wang T, Liu L, Fang J, Jin H, Natarajan S, Sheppard H, Lu M, Turner G, Confer T, Johnson M, Steinberg J, Ha L, Yadak N, Jain R, Picketts D, Ma X, Murphy A, Davidoff A, Glazer E, Easton J, Chen X, Wang R, Yang J. Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma. Cancer Research 2024, 85: 424-441. PMID: 39531507, PMCID: PMC11786959, DOI: 10.1158/0008-5472.can-24-1142.Peer-Reviewed Original ResearchPancreatic neuroendocrine tumorsC-MycCre recombinaseAnti-GD2 immunotherapyHigh-risk neuroblastomaDopamine B-hydroxylaseActivity of c-MycFDA-approved inhibitorC-Myc overexpressionC-Myc activityC-myc inductionTesting immunotherapyNeuroendocrine tumorsTargeted therapyTumor typesNeuroblastoma developmentNeuroblastoma tumorsNeuroblastoma oncogenesisEffective therapyTyrosine hydroxylaseTarget cellsTumorNeuroblastomaHuman neuroblastomaGenetic featuresBetween ‘NET’ and ‘CoGNET’: A biphasic Neuroendocrine-Gangliocytic tumor of the pancreas
Khandakar B, Ng M, Baum L, Robert M. Between ‘NET’ and ‘CoGNET’: A biphasic Neuroendocrine-Gangliocytic tumor of the pancreas. Human Pathology Reports 2024, 38: 300763. DOI: 10.1016/j.hpr.2024.300763.Peer-Reviewed Original ResearchNeuroendocrine tumorsLow-grade neuroendocrine tumorHead of pancreasNerve sheath tumorsClinico-pathological findingsPancreatic headSheath tumorsImmunohistochemical profilePeriampullary regionCase reportDifferential diagnosisGangliocytic paragangliomaTumorGangliocytic differentiationPancreasTumor classificationParaganglioma7168 Papillary thyroid carcinoma co-existing with intrathyroidal metastasis from lung neuroendocrine tumor
Balasubramanian P, Ladenheim A, Gilani S, Gibson C, Kunz P. 7168 Papillary thyroid carcinoma co-existing with intrathyroidal metastasis from lung neuroendocrine tumor. Journal Of The Endocrine Society 2024, 8: bvae163.2027. PMCID: PMC11453623, DOI: 10.1210/jendso/bvae163.2027.Peer-Reviewed Original ResearchLung neuroendocrine tumorsPapillary thyroid carcinomaNeuroendocrine tumorsThyroid carcinomaPapillary thyroid cancerIntrathyroidal metastasisThyroid cancerThyroid metastasisPET-CTThyroid nodulesMetastatic lung NETsLow-risk thyroid cancerLeft thyroid noduleCentral neck dissectionFDG PET-CTMedullary thyroid carcinomaTreatment response evaluationIncidental thyroid nodulesInitiation of treatmentYear old femaleDiagnosed primary malignancyRate of FDGCalcitonin stainingFinal pathologyNeck dissectionModern Management of Gastric Neuroendocrine Neoplasms
Kunstman J, Nagar A, Gibson J, Kunz P. Modern Management of Gastric Neuroendocrine Neoplasms. Current Treatment Options In Oncology 2024, 25: 1137-1152. PMID: 39083164, DOI: 10.1007/s11864-024-01207-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsG-NENsGastrin-secreting tumorsSurgical resectionHeterogeneous group of tumorsProton pump inhibitor usageResection of visible lesionsG-NEN patientsGroup of tumorsRisk of progressionHigh-risk lesionsMetastatic diseaseNeuroendocrine tumorsNeuroendocrine neoplasmsMetastatic spreadEndoscopic resectionEndoscopic surveillanceTreatment paradigmInhibitor usageNeuroendocrine diseaseResectionTumorLow riskVisible lesionsHeterogeneous groupDe-EscalationProteogenomic characterization of pancreatic neuroendocrine tumors uncovers hypoxia and immune signatures in clinically aggressive subtypes
Tanaka A, Ogawa M, Zhou Y, Otani Y, Hendrickson R, Miele M, Li Z, Klimstra D, Wang J, Roehrl M. Proteogenomic characterization of pancreatic neuroendocrine tumors uncovers hypoxia and immune signatures in clinically aggressive subtypes. IScience 2024, 27: 110544. PMID: 39206147, PMCID: PMC11350455, DOI: 10.1016/j.isci.2024.110544.Peer-Reviewed Original ResearchClinically aggressive subtypePancreatic neuroendocrine tumorsProteomic subtypesNeuroendocrine tumorsAggressive subtypeImmune hot tumorsSystemic treatment optionsVariable clinical outcomesTumor grading systemPredicting patient outcomesHot tumorsCytotoxic chemotherapyImmune signaturesImmunosuppressive moleculesImmunotherapy targetClinical aggressivenessSomatostatin analogsRecurrence rateClinical outcomesTreatment optionsEndocrine neoplasmsGlycolysis upregulationPanNETsProteogenomic characterizationInflammatory pathwaysOutcomes of repeat conventional transarterial chemoembolization in patients with liver metastases
Ghabili K, Windham-Herman A, Konstantinidis M, Murali N, Borde T, Adam L, Laage-Gaupp F, Lin M, Chapiro J, Georgiades C, Nezami N. Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases. Annals Of Hepatology 2024, 29: 101529. PMID: 39033928, PMCID: PMC11558520, DOI: 10.1016/j.aohep.2024.101529.Peer-Reviewed Original ResearchConventional transarterial chemoembolizationLiver metastasesNeuroendocrine tumorsColorectal carcinomaTransarterial chemoembolizationOverall survivalLung cancerAssociated with improved patient survivalManagement of liver metastasesMetastatic liver lesionsSingle-institution analysisNonresponding patientsSurvival outcomesPatient survivalResponse assessmentTarget lesionsMetastasisLiver lesionsPatientsResponse rateChemoembolizationSurvivalLiverLesionsCancer[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz P, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh D, Yoo C, Halfdanarson T, Falk S, Folitar I, Zhang Y, Aimone P, de Herder W, Ferone D, Investigators A. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. The Lancet 2024, 403: 2807-2817. PMID: 38851203, DOI: 10.1016/s0140-6736(24)00701-3.Peer-Reviewed Original ResearchGastroenteropancreatic neuroendocrine tumorsProgression-free survivalAdvanced gastroenteropancreatic neuroendocrine tumorsLong-acting octreotideLu-DOTATATENeuroendocrine tumorsGrade 2Open-labelControl groupTreated patientsWell-differentiatedStandard first-line treatment optionMedian progression-free survivalProgression-free survival eventsTreatment periodFirst-line treatment optionProgression-free survival analysisNeuroendocrine tumor gradingSomatostatin receptor-positiveFirst-line therapyInteractive response technologyHigh-dose octreotidePhase 3 studyPhase 3 trialStandard of care211MO First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study
Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz P, Chasen B, Capdevila J, Tafuto S, Oh D, Yoo C, Falk S, Halfdanarson T, Folitar I, Zhang Y, de Herder W, Ferone D. 211MO First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study. Annals Of Oncology 2024, 35: s92-s93. DOI: 10.1016/j.annonc.2024.05.219.Peer-Reviewed Original ResearchSafety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.
Kunz P, Ferone D, Halperin D, Myrehaug S, Herrmann K, Pavel M, Chasen B, Capdevila J, Tafuto S, Oh D, Yoo C, Falk S, Halfdanarson T, Folitar I, Zhang Y, de Herder W, Singh S. Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study. Journal Of Clinical Oncology 2024, 42: 4131-4131. DOI: 10.1200/jco.2024.42.16_suppl.4131.Peer-Reviewed Original ResearchTime to responseObjective response rateGastroenteropancreatic neuroendocrine tumorsLu-DOTATATEGEP-NETsAdverse eventsHematologic toxicityNeuroendocrine tumorsSafety profileSub-analysisMedian time to responseCases of myelodysplastic syndromeOctreotide long-actingHematologic adverse eventsProgression-free survivalTime to first occurrenceRandomized treatment periodFatal adverse eventsInfection rateDose interruptionCTCAE gradeRadioligand therapyMyelodysplastic syndromeEligible ptsLaboratory abnormalitiesPhase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.
Halperin D, Morris M, Ulaner G, Strosberg J, Mehr S, Li D, Soares H, Anthony L, Kotiah S, Jacene H, Tesselaar M, Kunz P, Ferreira D, Li J, Ma K, Rearden J, Moran S, Hope T, Singh S. Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings. Journal Of Clinical Oncology 2024, 42: 3091-3091. DOI: 10.1200/jco.2024.42.16_suppl.3091.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsPhase Ib portionDose-limiting toxicitySerious adverse eventsGEP-NETsSomatostatin analoguesAdverse eventsFrequent treatment-emergent adverse eventsEfficacy dataData review committeePlanned dose levelsProgression-free survivalDuration of responseGastroenteropancreatic neuroendocrine tumorsLonger-term safetyAlpha-emitting radiopharmaceuticalStandard of careDose holdRECIST v1.1Stable diseasePartial responseStarting doseTumor responseDose modificationNeuroendocrine tumors[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study
Ferone D, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz P, Chasen B, Capdevila J, Tafuto S, Oh D, Yoo C, Falk S, Halfdanarson T, Folitar I, Zhang Y, Santoro P, Aimone P, de H, Singh S. [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study. Endocrine Abstracts 2024 DOI: 10.1530/endoabs.99.oc7.2.Peer-Reviewed Original ResearchSingle-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage–tumor interaction axes among different lineages of pituitary neuroendocrine tumors
Lin S, Dai Y, Han C, Han T, Zhao L, Wu R, Liu J, Zhang B, Huang N, Liu Y, Lai S, Shi J, Wang Y, Lou M, Xie J, Cheng Y, Tang H, Yao H, Fang H, Zhang Y, Wu X, Shen L, Ye Y, Xue L, Wu Z. Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage–tumor interaction axes among different lineages of pituitary neuroendocrine tumors. Genome Medicine 2024, 16: 60. PMID: 38658971, PMCID: PMC11040908, DOI: 10.1186/s13073-024-01325-4.Peer-Reviewed Original ResearchConceptsTumor immune microenvironmentTumor-associated macrophagesTumor cell apoptosisTumor cellsImmune cellsNeuroendocrine tumorsQuantitative immunofluorescenceComposition of immune cellsInfiltration of immune cellsMultiplexed quantitative immunofluorescenceLevel of immune infiltrationScRNA-seqPituitary neuroendocrine tumorsCX3CR1+ macrophagesDiversity of tumorsCell apoptosisSignificance of macrophagesRNA sequencing samplesScRNA-seq dataCX3CR1+Subcutaneous xenograft experimentsImmune microenvironmentSingle-cell RNA sequencingImmunological environmentImmune infiltrationIndications and outcomes of liver transplantation for liver tumors in the United States
Okumura K, Dhand A, Hanna K, Misawa R, Sogawa H, Veillette G, Nishida S. Indications and outcomes of liver transplantation for liver tumors in the United States. Surgery In Practice And Science 2024, 17: 100245. PMID: 39845637, PMCID: PMC11749412, DOI: 10.1016/j.sipas.2024.100245.Peer-Reviewed Original ResearchBile duct cancerLiver transplantationLiver tumorsHepatocellular carcinomaLT recipientsBenign tumorsSecondary tumorsDuct cancerMultivariate Cox regression analysisHighest prevalence of hepatitis COutcome of liver transplantationMultivariate Cox proportional-hazards modelUnited Network for Organ Sharing databaseOutcomes of LTPrevalence of hepatitis CKaplan-Meier methodOne-year survivalCox regression analysisCox proportional-hazards modelProportional-hazards modelNeuroendocrine tumorsSurvival outcomesHepatitis CHepatic tumorsHigher BMI
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply